Stable Angina Pectoris: The Medical Management of Symptomatic Myocardial Ischemia

Canadian Journal of Cardiology

Volumn 28, Issue 2 SUPPL., 2012, Pages

  Parker, John D ^a   Parker, John O ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; IVABRADINE; METOPROLOL; NADOLOL; NICORANDIL; NIFEDIPINE; NITRATE; PINDOLOL; PROPRANOLOL; RANOLAZINE; TIMOLOL; TRIMETAZIDINE; VERAPAMIL;

CORONARY ARTERY DISEASE; EXERCISE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LONG TERM CARE; REVIEW; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

ANGINA, STABLE; CARDIOVASCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; HALF-LIFE; HEART RATE; HUMANS; MEDICATION THERAPY MANAGEMENT; MYOCARDIAL ISCHEMIA; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TIME; VASCULAR RESISTANCE;

EID: 84858331992     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.11.002     Document Type: Review

References (140)

1. Heberden W. Some account of a disorder of the breast. Proceedings of the Royal Society of London 1772, 2:59-67.
2. Osler W. Principles and Practice of Medicine 1892, D Appleton and Company, New York.
3. Anderson G.M., Lomas J. Monitoring the diffusion of a technology: coronary artery bypass surgery in Ontario. Am J Public Health 1988, 78:251-254.
4. Ugnat A.M., Naylor C.D. Trends in coronary artery bypass grafting in Ontario from 1981 to 1989. CMAJ 1993, 148:569-575.
5. Hassan A., Newman A., Ko D.T., et al. Increasing rates of angioplasty versus bypass surgery in Canada, 1994-2005. Am Heart J 2010, 160:958-965.
6. Naylor C.D., Ugnat A.M., Weinkauf D., Anderson G.M., Wielgosz A. Coronary artery bypass grafting in Canada: what is its rate of use?. Which rate is right?. CMAJ 1992, 146:851-859.
7. Dalen J.E., Goldberg R.J., D'Arpa D., et al. Coronary heart disease in Massachusetts: the years of change (1980-1984). Am Heart J 1990, 119:502-512.
8. Chow C.M., Donovan L., Manuel D., Johansen H., Tu J.V. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005, 21:1265-1271.
9. Cannon P.J., Connell P.A., Stockley I.H., Garner S.T., Hampton J.R. Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1988, 1:979-981.
10. Payne N., Saul C. Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality. BMJ 1997, 314:257-261.
11. Hemingway H., Langenberg C., Damant J., et al. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation 2008, 117:1526-1536.
12. Pocock S.J., Henderson R.A., Rickards A.F., et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995, 346:1184-1189.
13. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117-1124.
14. Cohen D.J., Van Hout B., Serruys P.W., et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med 2011, 364:1016-1026.
15. Ezekowitz M.D., Hossack K., Mehta J.L., et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J 1995, 129:527-535.
16. Tzivoni D., Kadr H., Braat S., et al. Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997, 96:2557-2564.
17. Parker J.O., Amies M.H., Hawkinson R.W., et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran efficacy study group. Circulation 1995, 91:1368-1374.
18. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
19. Parker J.O., Porter A., Parker J.D. Propranolol in angina pectoris. Comparison of long-acting and standard-formulation propranolol. Circulation 1982, 65:1351-1355.
20. Tardif J.C., Ford I., Tendera M., Bourassa M.G., Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005, 26:2529-2536.
21. Ruzyllo W., Tendera M., Ford I., Fox K.M. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007, 67:393-405.
22. Parker J.D., Parker J.O. Nitrate therapy for stable angina pectoris. N Engl J Med 1998, 338:520-531.
23. Fallen E.L., Nahmias C., Scheffel A., et al. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease. Circulation 1995, 91:1381-1388.
24. Zoghbi G.J., Dorfman T.A., Iskandrian A.E. The effects of medications on myocardial perfusion. J Am Coll Cardiol 2008, 52:401-416.
25. Lei B., Matsuo K., Labinskyy V., et al. Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci U S A 2005, 102:6966-6971.
26. Loke K.E., Laycock S.K., Mital S., et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 1999, 100:1291-1297.
27. DeMots H., Glasser S.P. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989, 13:786-795.
28. Parker J.O., Farrell B., Lahey K.A., Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987, 316:1440-1444.
29. Parker J.O. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993, 72:871-876.
30. Chrysant S.G., Glasser S.P., Bittar N., et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993, 72:1249-1256.
31. Munzel T., Daiber A., Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005, 97:618-628.
32. Gori T., Parker J.D. Nitrate tolerance: a unifying hypothesis. Circulation 2002, 106:2510-2513.
33. Gori T., Parker J.D. The puzzle of nitrate tolerance: pieces smaller than we thought?. Circulation 2002, 106:2404-2408.
34. Munzel T., Daiber A., Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011, 123:2132-2144.
35. Parker J.O., Vankoughnett K.A., Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose-response relation. Am J Cardiol 1986, 57:1-5.
36. Dalal J.J., Parker J.O. Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy. Am J Cardiol 1984, 54:286-288.
37. Sullivan M., Myers J., Buchanan N., Froelicher V. Effects of sublingual nitroglycerin on the gas exchange response to exercise in stable angina pectoris. Am J Cardiol 1993, 72:767-769.
38. Jneid H., Chandra M., Alshaher M., et al. Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation 2005, 111:2565-2571.
39. Guo Y., Stein A.B., Wu W.J., et al. Late preconditioning induced by NO donors, adenosine A1 receptor agonists, and delta1-opioid receptor agonists is mediated by iNOS. Am J Physiol Heart Circ Physiol 2005, 289:H2251-H2257.
40. Leesar M.A., Stoddard M.F., Dawn B., et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001, 103:2935-2941.
41. Savonitto S., Ardissiono D., Egstrup K., et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996, 27:311-316.
42. Fox K.M., Mulcahy D., Findlay I., Ford I., Dargie H.J. Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J 1996, 17:96-103. The Total Ischaemic Burden European Trial (TIBET).
43. Kawanishi D.T., Reid C.L., Morrison E.C., Rahimtoola S.H. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992, 19:409-417.
44. Glasser S.P., Gana T.J., Pascual L.G., Albert K.S. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am Heart J 2005, 149:e1-e9.
45. van Dijk R.B., Lie K.I., Crijns H.J. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988, 9:1194-1199.
46. De Divitiis O., Liguori V., Di Somma S., et al. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. Eur Heart J 1987, 8(suppl M):43-54.
47. Frishman W.H., Glasser S., Stone P., et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999, 83:507-514.
48. Schneider W., Maul F.D., Bussmann W.D., et al. Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment. Eur Heart J 1988, 9:149-158.
49. Kohli R.S., Rodrigues E.A., Hughes L.O., Lahiri A., Raftery E.B. Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. J Am Coll Cardiol 1987, 9:615-621.
50. Cocco G., Alfiero R. A double-blind dose-response study of amlodipine in patients with stable angina pectoris. Eur Heart J 1991, 12:169-174.
51. Kinnard D.R., Harris M., Hossack K.F. Endurance testing for evaluation of antianginal therapy with amlodipine, a calcium channel blocking agent. J Am Coll Cardiol 1988, 12:791-796.
52. De Servi S., Ferrario M., Ghio S., et al. Effects of diltiazem on regional coronary hemodynamics during atrial pacing in patients with stable exertional angina: implications for mechanism of action. Circulation 1986, 73:1248-1253.
53. Grossman E., Messerli F.H. Calcium antagonists. Prog Cardiovasc Dis 2004, 47:34-57.
54. Neglia D., Gallopin M., Marraccini P., et al. Effects of intravenous amlodipine on coronary hemodynamics in subjects with angiographically normal coronary arteries. J Cardiovasc Pharmacol 2002, 39:884-891.
55. Lüscher T.F., Pieper M., Tendera M., et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009, 30:1590-1597.
56. Mason R.P. Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am J Cardiol 2001, 88:2M-6M.
57. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990, 335:1109-1113.
58. Shinoda E., Yui Y., Kodama K., et al. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005, 45:1153-1158.
59. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995, 95:187-194.
60. Gori T., Mak S.S., Kelly S., Parker J.D. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 2001, 38:1096-1101.
61. Caramori P.R., Adelman A.G., Azevedo E.R., et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998, 32:1969-1974.
62. Gori T., Parker J.D. Long-term therapy with organic nitrates: the pros and cons of nitric oxide replacement therapy. J Am Coll Cardiol 2004, 44:632-634.
63. Sleight P. Beta-adrenergic blockade after myocardial infarction. N Engl J Med 1981, 304:837-838.
64. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981, 304:801-807.
65. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981, 2:823-827.
66. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
67. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
68. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
69. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
70. Rehnqvist N., Hjemdahl P., Billing E., et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996, 17:76-81.
71. Pepine C.J., Cohn P.F., Deedwania P.C., et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994, 90:762-768.
72. Furberg C.D., Psaty B.M., Meyer J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331.
73. Psaty B.M., Heckbert S.R., Koepsell T.D., et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995, 274:620-625.
74. Poole-Wilson P.A., Lubsen J., Kirwan B.A., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004, 364:849-857.
75. Banasiak W., Wilkins A., Pociupany R., Ponikowski P. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in poland. Results of the multicentre recent study. Kardiol Pol 2008, 66:642-649. [discussion: 650].
76. Pepine C.J., Abrams J., Marks R.G., et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994, 74:226-231.
77. Jackson G. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. Int J Clin Pract 2001, 55:256-261.
78. Strauss W.E., Parisi A.F. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. Ann Intern Med 1988, 109:570-581.
79. O'Keefe J.C., Creamer J.E., Banim S.O. Efficacy of nisoldipine combined with beta-adrenergic-blocking drugs in the treatment of chronic stable angina. Clin Cardiol 1987, 10:345-350.
80. Findlay I.N., MacLeod K., Gillen G., et al. A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. Br Heart J 1987, 57:336-343.
81. Uusitalo A., Arstila M., Bae E.A., et al. Metoprolol, nifedipine, and the combination in stable effort angina pectoris. Am J Cardiol 1986, 57:733-737.
82. Humen D.P., O'Brien P., Purves P., Johnson D., Kostuk W.J. Effort angina with adequate beta-receptor blockade: comparison with diltiazem alone and in combination. J Am Coll Cardiol 1986, 7:329-335.
83. Findlay I.N., MacLeod K., Ford M., et al. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J 1986, 55:240-245.
84. Strauss W.E., Parisi A.F. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 1985, 71:951-957.
85. Kenny J., Kiff P., Holmes J., Jewitt D.E. Beneficial effects of diltiazem and propranolol, alone and in combination, in patients with stable angina pectoris. Br Heart J 1985, 53:43-46.
86. Johnston D.L., Lesoway R., Humen D.P., Kostuk W.J. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, crossover study. Am J Cardiol 1985, 55:680-687.
87. Frishman W.H., Charlap S., Goldberger J., et al. Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension. Am J Cardiol 1985, 56:41H-46H.
88. Frishman W.H., Charlap S., Farnham D.J., et al. Combination propranolol and bepridil therapy in stable angina pectoris. Am J Cardiol 1985, 55:43C-49C.
89. Cella G., Scattolo N., Cappellato M.G., et al. Platelet factor 4 release induced by intravenous administration of heparin. Folia Haematol Int Mag Klin Morphol Blutforsch 1985, 112:165-174.
90. Boden W.E., Bough E.W., Reichman M.J., et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation 1985, 71:1197-1205.
91. Winniford M.D., Huxley R.L., Hillis L.D. Randomized, double-blind comparison of propranolol alone and a propranolol-verapamil combination in patients with severe angina of effort. J Am Coll Cardiol 1983, 1:492-498.
92. Johnston D.L., Gebhardt V.A., Donald A., Kostuk W.J. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography. Circulation 1983, 68:1280-1289.
93. Hung J., Lamb I.H., Connolly S.J., et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation 1983, 68:560-567.
94. Subramanian B., Bowles M.J., Davies A.B., Raftery E.B. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol 1982, 49:125-132.
95. Packer M., Frishman W.H. Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective. Am J Cardiol 1982, 50:881-885.
96. Jenkins R.M., Nagle R.E. The symptomatic and objective effects of nifedipine in combination with beta-blocker therapy in severe angina pectoris. Postgrad Med J 1982, 58:697-700.
97. Tweddel A.C., Beattie J.M., Murray R.G., Hutton I. The combination of nifedipine and propranolol in the management of patients with angina pectoris. Br J Clin Pharmacol 1981, 12:229-233.
98. Leon M.B., Rosing D.R., Bonow R.O., Lipson L.C., Epstein S.E. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981, 48:131-139.
99. Lynch P., Dargie H., Krikler S., Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination. Br Med J 1980, 281:184-187.
100. Kenmure A.C., Scruton J.H. A double-blind controlled trial of the anti-anginal efficacy of nifedipine compared with propranolol. Br J Clin Pract 1979, 33:49-51.
101. Ekelund L.G., Oro L. Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study. Clin Cardiol 1979, 2:203-211.
102. Packer M. Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989, 320:709-718.
103. Canadian Cardiovascular Society 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 1998, 14(suppl C):1C-23C.
104. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation 2003, 107:149-158.
105. Fox K., Garcia M.A., Ardissino D., et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006, 27:1341-1381.
106. McGillion M., Arthur H.M., Cook A., et al. Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines. Can J Cardiol 2012, 28(suppl):S20-S41.
107. Tardif J.C., Ponikowski P., Kahan T. Efficacy of the i(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009, 30:540-548.
108. Hayata N., Araki H., Nakamura M. Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. Am Heart J 1986, 112:1245-1250.
109. Kato K., Asanoi H., Wakabayashi C., et al. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test. J Cardiovasc Pharmacol 1987, 10(suppl 8):S98-S103.
110. Meany T.B., Richardson P., Camm A.J., et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989, 63:66J-70J.
111. Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol 1983, 5:364-370.
112. Holzmann S., Kukovetz W.R., Braida C., Poch G. Pharmacological interaction experiments differentiate between glibenclamide-sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil. Eur J Pharmacol 1992, 215:1-7.
113. Miura T., Miki T. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol 2003, 1:251-258.
114. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990, 4:1075-1088.
115. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial [erratum in 2002;360:806]. Lancet 2002, 359:1269-1275. IONA Study Group.
116. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010, 106:434-446.
117. Tardif J.C. Heart rate as a treatable cardiovascular risk factor. Br Med Bull 2009, 90:71-84.
118. DiFrancesco D., Borer J.S. The funny current: cellular basis for the control of heart rate. Drugs 2007, 67(suppl 2):15-24.
119. f selective channel inhibitor ivabradine in the treatment of chronic stable angina. Adv Ther 2009, 26:127-137.
120. Tardif J.C. Clinical results of I(f) current inhibition by ivabradine. Drugs 2007, 67(suppl 2):35-41.
121. Borer J.S., Fox K., Jaillon P., Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003, 107:817-823.
122. Szwed H., Sadowski Z., Elikowski W., et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). Trimetazidine in Poland. Eur Heart J 2001, 22:2267-2274.
123. Ciapponi A., Pizarro R., Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005, CD003614.
124. Anderson J.R., Khou S., Nawarskas J.J. Ranolazine: a potential new treatment for chronic stable angina. Heart Dis 2001, 3:263-269.
125. Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep 2005, 7:63-70.
126. Stanley W.C. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Ther 2004, 9(suppl 1):S31-S45.
127. Chaitman B.R. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004, 9(suppl 1):S47-S64.
128. Zaza A., Belardinelli L., Shryock J.C. Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther 2008, 119:326-339.
129. Hasenfuss G., Maier L.S. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol 2008, 97:222-226.
130. Saint D.A. The cardiac persistent sodium current: an appealing therapeutic target?. Br J Pharmacol 2008, 153:1133-1142.
131. Maier L.S. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 2009, 54:279-286.
132. Belardinelli L., Shryock J.C., Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006, 92(suppl 4):iv6-iv14.
133. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
134. Stone P.H., Gratsiansky N.A., Blokhin A., Huang I.Z., Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006, 48:566-575.
135. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775-1783.
136. Kannel W.B., Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol 1972, 29:154-163.
137. Burggraf G.W., Parker J.O. Prognosis in coronary artery disease. Angiographic, hemodynamic, and clinical factors. Circulation 1975, 51:146-156.
138. Juul-Moller S., Edvardsson N., Jahnmatz B., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) group. Lancet 1992, 340:1421-1425.
139. Hjemdahl P., Eriksson S.V., Held C., et al. Favourable long term prognosis in stable angina pectoris: an extended follow-up of the angina prognosis study in Stockholm (APSIS). Heart 2006, 92:177-182.
140. Chaitman B.R., Hardison R.M., Adler D., et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529-2540.